Cancers, Free Full-Text

Overexpression of Exportin-1 (XPO1), a key regulator of nuclear-to-cytoplasmic transport, is associated with inferior patient outcomes across a range of adult malignancies. Targeting XPO1 with selinexor has demonstrated promising results in clinical trials, leading to FDA approval of its use for multiple relapsed/refractory cancers. However, XPO1 biology and selinexor sensitivity in childhood cancer is only recently being explored. In this review, we will focus on the differential biology of childhood and adult cancers as it relates to XPO1 and key cargo proteins. We will further explore the current state of pre-clinical and clinical development of XPO1 inhibitors in childhood cancers. Finally, we will outline potentially promising future therapeutic strategies for, as well as potential challenges to, integrating XPO1 inhibition to improve outcomes for children with cancer.

A Randomized Trial of Letrozole in Postmenopausal Women after Five

Journal of Cancer Research and Clinical Oncology

Multimodal analysis of methylomics and fragmentomics in plasma

Multi-omics integrated circulating cell-free DNA genomic

Prostate Cancer.Csv - Colaboratory

Radical causes of cancer

Celltracker Zip Get File - Colaboratory

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Thoracic Cancer - Wiley Online Library

8 Ways to prevent cancer & be healthy -Siteman Cancer Center